Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs

Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs

Darshan Mehta,1 Matthew Davis,2 Andrew J Epstein,3 Brian Wensel,1 Todd Grinnell,4 G Rhys Williams1 1Sunovion Pharmaceuticals Inc., Marlborough, MA, USA; 2Medicus Economics, LLC, Milton, MA, USA; 3Medicus Economics, LLC, Philadelphia, PA, USA; 4Medical Affairs, Sunovion Pharmaceuticals Inc., Marlboro...

Full description

Bibliographic Details
Main Authors: Mehta D, Davis M, Epstein AJ, Wensel B, Grinnell T, Williams GR
Format: Article
Language:English
Published: Dove Medical Press 2021-04-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
eslicarbazepine acetate
focal seizures
healthcare resource utilization
medical charges
Online Access:https://www.dovepress.com/comparative-economic-outcomes-in-patients-with-focal-seizure-initiatin-peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/comparative-economic-outcomes-in-patients-with-focal-seizure-initiatin-peer-reviewed-fulltext-article-CEOR

Similar Items